ImpriMed, Inc.
PrivateLast Round
Series A
Dec 19, 2023
Total Funding Raised
$26.7M
Company Overview
ImpriMed, Inc. is a precision medicine company founded in 2017 that utilizes artificial intelligence and lab testing of live cancer cells to predict patient response to various cancer treatments. The company's platform was first commercialized in the veterinary field, providing personalized drug response profiles for dogs and cats with blood cancers to veterinary oncologists. After raising $23 million in a Series A funding round in late 2023, ImpriMed is expanding its technology into human oncology. The company's goal is to provide data-driven technology to help doctors and veterinarians select the most effective, personalized medicinal regime for each patient.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Medical AI, Drug Discovery
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImpriMed, Inc. Comps
Public and private peers based on sector, stage, and business model.
ImpriMed, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 19, 2023 | ||||
| VC Round | Apr 13, 2021 | ||||
| Seed | Apr 12, 2019 |
Key People
Founding team and executive leadership
ImpriMed, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Draper Dragon | VC Round |
| Han River Partners | Series A |
| Murex Partners | VC Round, Series A, Seed |
| ES Investor | VC Round |
| Stanford-StartX Fund | Seed |
| SBVA | Series A |
| Ignite Innovation Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Helped over 11,000 dogs and cats with cancer.
- Mar 4, 2026
Reached 288 specialty hospital customers in the US.
ImpriMed, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImpriMed, Inc.'s valuation, stock price, and market status.
